Antibody responses to the merozoite surface protein-1 complex in cerebral malaria patients in India by Lucchi, Naomi W et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
Malaria Journal
Open Access Research
Antibody responses to the merozoite surface protein-1 complex in 
cerebral malaria patients in India
Naomi W Lucchi1, Jon Eric Tongren1, Vidhan Jain2, Avinash C Nagpal3, 
Christian W Kauth4, Ute Woehlbier4, Hermann Bujard4, Aditya P Dash5, 
Neeru Singh2, Jonathan K Stiles6 and Venkatachalam Udhayakumar*1,7
Address: 1Malaria Branch, Division of Parasitic Diseases, National Center for Zoonotic, Vector-Borne and Enteric Diseases, Coordinating Center 
for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA, 2National Institute of Malaria Research, Regional Medical 
Research Center for Tribals, Indian Council of Medical Research (ICMR), Jabalpur, India, 3Nethaji Subash Chandra Bose (NSCB) Medical College, 
Jabalpur, India, 4Zentrum fuer Molekulare Biologie Heidelberg (ZMBH), Universitaet Heidelberg, Im Neuenheimer Feld 282, D-69120 
Heidelberg, Germany, 5National Institute of Malaria Research, ICMR, New Delhi, India, 6Morehouse School of Medicine, Atlanta, GA, USA and 
7Atlanta Research and Education Foundation, Decatur, GA, USA
Email: Naomi W Lucchi - frd9@cdc.gov; Jon Eric Tongren - Tongren@maine.gov; Vidhan Jain - vidhanjain78@yahoo.com; 
Avinash C Nagpal - nagpal_avinash@yahoo.com; Christian W Kauth - C.Kauth@gdels.de; Ute Woehlbier - uwoehlbier@yahoo.de; 
Hermann Bujard - h.bujard@zmbh.uni-heidelberg.de; Aditya P Dash - apdash2@rediffmail.com; Neeru Singh - neeru.singh@gmail.com; 
Jonathan K Stiles - jstiles@msm.edu; Venkatachalam Udhayakumar* - vxu0@cdc.gov
* Corresponding author    
Abstract
Background: Plasmodium falciparum infection causes cerebral malaria (CM) in a subset of patients
with anti-malarial treatment protecting only about 70% to 80% of patients. Why a subset of malaria
patients develops CM complications, including neurological sequelae or death, is still not well
understood. It is believed that host immune factors may modulate CM outcomes and there is
substantial evidence that cellular immune factors, such as cytokines, play an important role in this
process. In this study, the potential relationship between the antibody responses to the merozoite
surface protein (MSP)-1 complex (which consists of four fragments namely: MSP-183, MSP-130, MSP-
138 and MSP-142), MSP-636 and MSP-722 and CM was investigated.
Methods: Peripheral blood antibody responses to recombinant antigens of the two major allelic
forms of MSP-1 complex, MSP-636 and MSP-722 were compared between healthy subjects, mild
malaria patients (MM) and CM patients residing in a malaria endemic region of central India. Total
IgG and IgG subclass antibody responses were determined using ELISA method.
Results: The prevalence and levels of IgG and its subclasses in the plasma varied for each antigen.
In general, the prevalence of total IgG, IgG1 and IgG3 was higher in the MM patients and lower in
CM patients compared to healthy controls. Significantly lower levels of total IgG antibodies to the
MSP-1f38, IgG1 levels to MSP-1d83, MSP-119 and MSP-636 and IgG3 levels to MSP-1f42 and MSP-722
were observed in CM patients as compared to MM patients.
Conclusion: These results suggest that there may be some dysregulation in the generation of
antibody responses to some MSP antigens in CM patients and it is worth investigating further
whether perturbations of antibody responses in CM patients contribute to pathogenesis.
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Background
One life-threatening complication of Plasmodium falci-
parum infection is cerebral malaria (CM). This complex
syndrome affects mainly young children (two to six years
old) in sub-Saharan Africa with an estimated incidence of
1.12 cases per 1,000 children per year and an estimated
mortality of 18.6% [1]. In addition, a subset of CM survi-
vors have an increased risk of developing persistent neu-
rocognitive sequelae post-recovery [2-4] and reviewed in
[5]. In Asia and South America, where the intensity of P.
falciparum is much lower than in Africa, all age groups are
at risk for CM [1,6-9]. The pathogenesis of CM is complex
and it is still poorly understood as to why only a subset of
patients develop CM. Various factors, such as sequestra-
tion of infected erythrocytes, and inflammatory cytokines
and chemokines, have been postulated to play major roles
in CM pathogenesis [10-17]. The role of antibodies in CM
pathogenesis or protection is not well understood.
The merozoite surface protein (MSP)-1, a large multipro-
tein complex exposed on the surface of merozoites, is one
of the well characterized antigens of P. falciparum. During
late schizogony, MSP-1 is proteolytically processed from
its ~190 kDa precursor into four major cleavage products:
p83, p30, p38, and p42 [18] designated as MSP-183, MSP-
130, MSP-138 and MSP-142 respectively. During erythrocyte
invasion, the MSP-142 fragment is further cleaved into
MSP-133 and MSP-119 which is essential for invasion (Fig-
ure 1A) [19]. The proteolytically processed MSP-1 appears
to exist in association with the processed products of MSP-
6 and MSP-7 (Figure 1B) [20-22]. Major biochemical and
immunological parameters of this multipartite have been
described recently [23].
Humoral immune responses to MSP-1 protein subunits,
especially, MSP-142 and MSP-119 fragments, are known to
be protective against P. falciparum infection and clinical
malaria [24-33]. Antibodies specific for these antigens
have been shown to inhibit both erythrocyte invasion and
parasite growth in vitro [26,27]. In some studies, antibody
responses to MSP-119 were correlated with clinical immu-
nity to P. falciparum [29,30,34] and with reduced parasi-
taemia and fever [31]. In addition, presence of several T-
cell epitopes within the MSP-142 fragment were identified
[35] and these epitopes may provide T- helper function
needed for the production of anti-MSP-1 antibodies.
Studies of the msp-1 gene sequence obtained from differ-
ent P. falciparum isolates demonstrate significant antigenic
diversity comprising highly conserved, dimorphic and
variable regions. There are two major allelic forms of MSP-
1 belonging to either the K1, (as in the FCB-1 strain, here
referred to as F allelic form) or the MAD20 (as in the 3D7
strain, here referred to as D allelic form) allelic families
[36,37]. Therefore, one would postulate that naturally
exposed individuals would mount immune responses to
different fragments and allelic forms of MSP-1. However,
only a few field studies have investigated humoral
responses to both of these allelic forms of the four major
subunits of MSP-1 and their associated proteins, MSP-636
and MSP-722[25,38-40] in humans naturally exposed to
malaria. A complete characterization of humoral immune
responses to this complex protein is therefore required to
determine their role in protective immunity and patho-
genesis.
The potential adverse effect of malarial antibody
responses, including antibodies to the C-terminal region
of MSP-1, in the manifestation of CM have been impli-
cated in some studies [41-45]. For example, higher levels
of IgM and IgG antibodies to glycosylphosphatidylinosi-
tols (GPI) were associated with CM and death in young
children in a study conducted in Mali [45]. On the con-
trary, in another study, reduced anti-GPI antibodies were
found in CM patients compared to mild malaria patients
[41]. In a Ghanaian study, IgG2 and IgG4 antibody
responses to a recombinant P. falciparum RIFIN antigen,
RIF-29, were exclusively shown to be associated with CM,
suggesting that these antibodies might be involved in CM
pathogenesis [44].
In the current study, the antibody response to the two
major allelic forms (F and D) of MSP-1 antigens (MSP-183,
MSP-130, MSP-138 and MSP-142) and their associated pro-
teins, MSP-636 and MSP-722, was systematically character-
ized in an Indian cohort and the responses compared
between two different group of malaria patients and
healthy controls.
Materials and methods
Study area
The blood samples for this study came from a subset of
121 subjects enrolled in a cohort study designed to assess
the severe outcomes associated with CM in the Jabalpur
Province of Madhya Pradesh state in India. The study sites
included Nethaji Subash Chandra Bose (NSCB) Hospital
(a referral hospital for the region) in Jabalpur and Civic
Hospital (primary hospital) in Maihar, Satna District. This
study was approved by the ethical committees of More-
house School of Medicine, National Institute of Malaria
Research in India, Centers for Disease Control and Pre-
vention (CDC) and the National Institute of Health
(NIH) in the USA. Jabalpur province is a malaria endemic
region with seasonal transmission of malaria accounting
for about 23% of all the malaria cases in Madhya Pradesh
state [46]. Previous community based studies conducted
in this area revealed that malaria affects all age groups
with the highest prevalence occurring in children between
8–14 years of age [47].Malaria Journal 2008, 7:121 http://www.malariajournal.com/content/7/1/121
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Schematic representation of the MSP-1 and MSP-1/MSP-6/MSP-7 complex antigens used in the study Figure 1
Schematic representation of the MSP-1 and MSP-1/MSP-6/MSP-7 complex antigens used in the study. The sche-
matic representation of the MSP-1 protein is shown (A). The MSP-1 precursor protein (i) undergoes proteolytic cleavage into 
four subunits as shown (ii). The MSP-142 molecule is further cleaved to MSP-133 and MSP-119 (iii). A proposed model (adapted 
from [23]) demonstrating the interactions of MSP-1 protein with the MSP-636 and MSP-722 molecules (B). The two allelic forms 
of MSP-183, MSP-130, MSP-138 and MSP-142 (D and F), in addition to MSP-636, MSP-722 and MSP-119, were expressed in E. coli and 
purified [49,50]. The purity of these recombinant proteins was examined by using 12% SDS-PAGE followed by Coomassie 
staining (C). Molecular weight (MW) is shown in kDa.
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Study details
Three categories of subjects, namely cerebral malaria
(CM) patients, mild malaria (MM) patients and healthy
control (HC) subjects were enrolled in the study after the
informed consent was obtained. Patients from all ages
and both sexes who met the study criteria were enrolled.
The presence of P. falciparum parasitaemia was deter-
mined by microscopic examination of thin and thick
smears. Clinical histories and information were collected
for each patient from physician's records and study ques-
tionnaires. The following criteria to enroll the subjects
into the different clinical groups were used:
Cerebral malaria (CM)
CM was defined as unrousable coma (a non-purposeful
response or no response to a painful stimulus) with
microscopically diagnosed P. falciparum and have no
other clinically evident cause of impaired consciousness
such as hypoglycemia, meningitis, and encephalitis fol-
lowing WHO criteria [48]. Patients with mixed infection
of malaria parasites were excluded.
Mild malaria (MM)
Patients who had fever with P. falciparum parasitaemia of
< 25,000 parasites/μl of blood with no evidence of
impaired consciousness or seizures at the time of enroll-
ment with no other past history of mental illness, menin-
gitis or accidental head injury were included.
Healthy control (HC)
HC were recruited from relatives of the patients or persons
residing in the same study area who did not have malaria
infection (as determined by microscopy) or any other
febrile illness at the time of enrollment.
Blood collection
Venous blood samples were collected from children (5
ml) and adults (10 ml) into Becton-Dickinson cell prepa-
ration tubes (catalogue #362753, BD Pharmingen, Frank-
lin Lakes, NJ, USA). The blood was centrifuged for 20
minutes at 1500 relative centrifugal force (rcf) to separate
plasma. Plasma samples were aliquoted and frozen imme-
diately in liquid nitrogen or at 80°C until use.
Plasmodium falciparum antigens
Relatively pure recombinant antigens of the major
processing products of MSP-1 [MSP-183, MSP-130, MSP-
138 and MSP-142 belonging to both the K1 allelic form (as
in the FCB-1 strain, here referred to as F), and the MAD20
allelic form (as in the 3D7 strain, here referred to as D)]
together with MSP-119 (3D7), MSP-636 (3D7) and MSP-
722 (3D7) were used. These antigens were prepared as
described previously [23,49,50] and the purity of the
products that were used in this study are shown in Figure
1C.
Enzyme-linked immunosorbent assay (ELISA)
Microtiter Immulon-2 plates were coated overnight with
the MSP complex antigens (500 ng/ml) in phosphate
buffered solution at 4°C. Total IgG antibodies were meas-
ured using a HRP-conjugated mouse anti-human IgG
antibody at 1:8000 dilution (Southern Biotech, Birming-
ham, AL). IgG subclasses were measured using mouse
anti-human IgG subclass antibodies IgG1 (HP6069) at
1:2000, IgG2 (HP6002) at 1:6000, IgG3 (HP6047) at
1:50,000 and IgG4 (HP6023) at 1:20,000 dilution fol-
lowed by goat anti-mouse IgG-HRP at 1:2000 dilution
(Southern Biotech, Birmingham, AL). Samples were tested
at a 1:400 dilution and 1:100 dilution for total IgG and
subclasses respectively. Ten pooled plasma samples from
malaria naïve donors from USA were selected and used as
negative controls in each experiment. In addition, each
ELISA plate contained a duplicate of blank wells with no
plasma sample and the mean background OD value
obtained from these wells was subtracted from all other
experimental wells. Test samples were considered positive
when the OD values were higher than the mean OD plus
two standard deviations of pooled negative control sera.
The percentage prevalence was calculated as: (total
number of positive sera/total number of sera tested) ×
100.
Statistical analysis
ELISA absorbance values (measured as optical density,
OD) were compared and analysed by a non-parametric
test (Kruskal-Wallis test). Differences in the percentage
prevalence of the antibodies were calculated using a mul-
tiple comparison analysis controlling for age and parasi-
taemia. Antibody levels for the different subgroups of
MSP-1 antigens (D and F) were assessed for correlation by
Spearman's rank correlation. All statistical tests were per-
formed using STATA™ 8.2 (College Station, TX, USA) and
SAS (9.1, NC, USA).
Results
Study samples
The characteristics of subjects who participated in this
study are summarized in Table 1. Among the 121 samples
tested for total IgG, 16% were from patients in the HC cat-
egory, 38% from MM and 46% from CM. Of the 120 sam-
ples tested for the subclasses, 15% were from HC, 41%
from MM and 44% from CM (Table 1).
Prevalence and levels of total IgG antibodies to various 
antigens of MSP-1 complex
As shown in Figure 2, total IgG antibody prevalence to the
different antigens varied greatly. Overall, the highest prev-
alence of IgG response was seen in the MM group fol-
lowed by the CM group and the HC group, the latter
showing the lowest prevalence with a few exceptions.
However, these differences were significantly differentMalaria Journal 2008, 7:121 http://www.malariajournal.com/content/7/1/121
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between HC and MM groups only for MSP-1d38 (P <
0.006), MSP-1d42 (P < 0.003) and MSP-119 (P < 0.01) anti-
gens. MSP-1d30 and MSP-1f30 showed the lowest responses
while the MSP-1f38, MSP-1d83, MSP-1f83 and MSP-636 anti-
gens showed the highest responses. The F allelic forms of
MSP-130  and MSP-138  demonstrated higher responses
compared to the D allelic forms.
The mean antibody levels reported in Figure 3 illustrate
important differences in the IgG antibody levels between
the three groups. Significantly higher levels of antibody
responses in the MM group compared to the HC group
were observed for MSP-1d38, MSP-1d42, MSP-119 and MSP-
636 antigens (P < 0.05). The CM and the HC group had
similar levels of antibodies except in the case of MSP-119,
which showed higher levels of antibody responses in the
CM group compared to HC group (P < 0.05). Although
there was a trend towards lower levels of antibody
responses in CM as compared to the MM group for several
antigens, the difference was significant only for MSP-1f83
(P < 0.05).
IgG subclass responses to MSP complex antigens
As previously reported [51], a skewing towards IgG1 and
IgG3 subclasses in the prevalence and levels of antibody
responses to most of the antigens was observed. IgG2 and
IgG4 responses were generally very low with a few excep-
tions (Figures 4). Interestingly, all the plasmas were posi-
tive for anti-MSP-1f38 IgG3 and IgG4 (100% prevalence)
regardless of disease category (Figure 4). As observed with
total IgG responses, the MM group showed higher preva-
lence of IgG1 responses to eight antigens and IgG3
responses to for five antigens compared to HC. The CM
group showed higher prevalence of IgG1 responses to
three antigens and higher IgG3 responses to two antigens
as compared to the HC group. Significantly lower preva-
lence of anti- MSP-1f30 and MSP-1f42 IgG1 (p < 0.05), anti-
MSP-1d83, MSP-636 and MSP-722 IgG3 (p < 0.05) and anti-
MSP-1d38 and MSP-636 IgG2 (p < 0.05) were observed in
CM patients compared to MM patients. The prevalence of
IgG2 antibody responses was below 20% for all antigens
except for MSP-1d38, MSP-1d83 (in MM cases) and MSP-
636. Only MSP-1f38, MSP-1d42  and MSP-1d83  antigens
showed IgG4 antibody in more than 20% of the patients
and there were little differences in the prevalence of IgG4
responses among the three patient categories.
The differences in the median of antibody levels (IgG1
and IgG3) are reported in Figure 5. IgG2 and IgG4
responses were not included as there were only negligible
amounts of antibodies present. Some antigens, such as
MSP-1f42, MSP-1f83, MSP-119 and MSP-722, evoked more
IgG1 antibodies than IgG3 while MSP-1d30, MSP-1f30 and
MSP-1f38 elicited more IgG3 antibodies than other sub-
classes. Significantly higher levels of IgG1 for 8 antigens
and IgG3 for five antigens antibody levels were found in
MM patients compared to HC. The CM group showed
higher levels of IgG1 for six antigens (Figure 5A) and IgG3
for two antigens as compared to HC (Figure 5B). Signifi-
cantly lower antibody levels in CM patients compared to
MM patients for anti- MSP-1d83, MSP-119 and MSP-636
IgG1 antibodies (P < 0.05) (Figure 5A) and anti- MSP-1f42
and MSP-722 IgG3 antibodies (P < 0.05) (Figure 5B) were
observed.
Correlation of the two dimorphic alleles of MSP-1 antigens 
for total IgG
In order to examine to what extent the two alleles are
related to each other in terms of eliciting antibody
responses, correlations in antibody responses between the
two allelic forms were determined. In general, there was a
strong correlation in the IgG antibody responses between
MSP-138,, MSP-142 and MSP-183 allelic forms. The correla-
tion was lowest for the MSP-130 antigen (Figure 6). A sim-
ilar result was observed for IgG1 (p30; r2 = 0.4, p38; r2 =
0.7, p42; r2 = 0.6, p83; r2= 0.4) and IgG3 (p30; r2 = 0.5,
p38; r2  = 0.7, p42; r2  = 0.6, p83; r2 = 0.7) antibody
responses.
Table 1: Characteristics of the study participants
HC MM CMa
Total No. of samples for IgG 19 46 56
Total No. of samples for subclasses 18 49 53
No. of males used for total IgG 52 0 1 8
No. of males used for subclasses 42 8 3 6
No. of females used for total IgG 14 26 38
No. of females used for subclasses 14 21 17
Median age for samples used for total IgG (yr) 30.0 18.5 22.0
Median age for samples used for subclasses (Yr) 27.0 19.0 22.0
Median parasitaemia (parasite/μl) of samples used for total IgG N/A 1,507 960
Median parasitaemia (parasite/μl) of samples used for subclasses N/A 1,413 987
The demographic and parasitological characteristics of the study participants are shown. A total of 121 samples were used for the total IgG assay 
and 120 for the IgG subclasses assay. HC = healthy controls, MM = mild malaria and CM = cerebral malaria. Seven patients in the CM group died of 
CM. Both age and parasitaemia data are represented as median. a CM patients include seven patients who died of CMMalaria Journal 2008, 7:121 http://www.malariajournal.com/content/7/1/121
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Discussion
In this study the differences in antibody responses to MSP
complex proteins among CM patients, MM patients and
HC subjects in a malaria-endemic part of India was inves-
tigated. This is one of the first studies to address systemat-
ically the antibody responses to the two major allelic
forms of all the four major subunits of MSP-1 antigens
(MSP-130 MSP-138 MSP-183, MSP-142) together with their
associated proteins, MSP-636  and MSP-722  in malaria
patients. The HC group tended to have lower antibody
levels than MM and CM patients consistent with previous
studies, which demonstrated that antibodies to merozoite
antigens were higher in parasitaemic compared to apara-
sitaemic subjects [38,52-54]. An important finding is the
observation that CM patients showed significantly lower
antibody responses to some of the MSP family of antigens
as compared to MM patients. These differences included
both low prevalence and low mean IgG levels and IgG
subclasses in the CM group. On the contrary, MM patients
showed significantly elevated IgG responses to many of
the antigens compared to the HC group.
The association of lower antibody titers to certain P. falci-
parum antigens with malaria severity (such as CM) has
been demonstrated in previous studies. For example, sig-
nificantly lower levels of P. falciparum anti-GPI IgGs were
observed in CM patients as compared to MM patients in a
study in Senegal [41]. In the Senegal study, the differences
in the responses to MSP-119 antigen were slightly lower in
the CM patients compared to the MM patients, although
significantly lower levels were only observed in the CM
non-survivors sub-group. In the current study, antibody
Prevalence of anti-MSP total IgG for the different subunits Figure 2
Prevalence of anti-MSP total IgG for the different subunits. The total IgG antibody response to the various MSP-1 sub-
units, MSP-636 and MSP-722 was measured by ELISA. The percentage prevalence was calculated as follows; (total number of pos-
itive sera/total number of sera tested) × 100. The prevalence of total IgG antibodies was statistically different between HC and 
MM for the indicated antigens (* = P < 0.05).
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responses to the MSP-119 antigen and some other MSP
complex antigens were lower in CM patients as compared
to MM patients. On the contrary, other studies have
reported higher levels of anti- GPI antibodies in CM
patients compared to non-severe malaria patients or HC
subjects [45]. In another study, higher levels of IgG2 and
IgG4 antibody responses to the variant surface glycopro-
tein RIF-29 were found exclusively in CM children but not
in the non-cerebral malaria controls [44]. Overall, find-
ings from the current study are consistent with the
hypothesis that CM patients may have some deficiency in
mounting optimal antibody responses to some antigens
essential for clinical protection. However, additional evi-
dence to confirm this hypothesis is required and valida-
tion will depend on further studies.
The seropositivity of antibodies varied considerably
depending on the MSP antigen as previously demon-
strated [39]. Antibody responses were relatively high for
most of the antigens, which was not surprising given that
this study was conducted in a malaria endemic region
where the majority of people are exposed to malaria. Both
MSP-142 and MSP-183 demonstrated high antibody preva-
lence compared to the other fragments, consistent with a
previous study [39]. Anti-MSP-636 antibodies were shown
to be generated in individuals naturally infected with P.
falciparum  [55]. Additionally, these antibodies were
thought to play a role in the inhibition of erythrocyte
invasion [55,56] and parasite multiplication [23,57]. This
study demonstrates that naturally exposed residents in
central India also generate both anti-MSP-636 and anti-
MSP-722 antibodies. In contrast, the antibody prevalence
to the MSP-1d30 antigen was low as had been observed in
previous studies [39], suggesting that this may be a poorly
immunogenic antigen.
Results from this study confirm that the entire MSP-1/
MSP-6/MSP-7 complex contains B-cell epitopes capable
of generating specific antibodies in naturally exposed
individuals.
Levels of total IgG antibody responses to MSP-1 subunits, MSP-636 and MSP-722 antigens Figure 3
Levels of total IgG antibody responses to MSP-1 subunits, MSP-636 and MSP-722 antigens. Total IgG antibody 
responses were measured. Box plots depict median values with 25th- and 75th-percentile values represented by the bottom 
and top edges of boxes. Small diamonds indicate values that fall outside of the error bars. Only a few antigens demonstrated 
statistically significant differences (* = p < 0.05) when the antibody levels were compared among the different disease catego-
ries. The different subunits and allelic forms of MSP-1 are represented as d30, f30, d38, f38, d42, f42, d83 and f83.
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The F allelic form of MSP-130  and MSP-138  antigens
showed higher seroprevalence than the corresponding D
allelic forms, suggesting that individuals generate specific
antibodies to the different allelic forms of these antigens.
The higher prevalence of antibodies to the F allelic forms
of MSP-130 and MSP-138 antigens may be due to a pre-
dominant presence of P. falciparum parasites with this
allele in this population in India. However, there is no
published information to verify the relative proportions
of these alleles within this population. A few studies that
have investigated the prevalence of the different MSP-1
alleles in India have either demonstrated the predomi-
nance of the MAD20 allele (D), as defined by sequence
analysis of the 16th and 17th block [58], or no bias to any
allele [59,60].
However, the MSP-142 and MSP-183 antigens showed sim-
ilar antibody prevalence to the two allelic forms of the
antigens, suggesting the development of antibodies cross
reactive to both allelic forms. Significant correlations in
the antibody levels elicited by the two allelic forms of
MSP-1 were observed except for the p30 fragment. The
MSP-130 is located within the dimorphic region of the
MSP-1 protein [36]. Therefore, different epitopes in these
dimorphic regions may be presented to B-cells generating
heterogeneity in antibody responses between the two alle-
les. These results demonstrate that, at least for p38, p42
and p83, responses to one allelic form predict positive
responses to the other allelic form. It is possible that con-
served epitopes between the two allelic forms are pre-
sented to the immune system leading to the generation of
Prevalence of anti-MSP IgG subclasses for the different subunits Figure 4
Prevalence of anti-MSP IgG subclasses for the different subunits. The prevalences of the four IgG subclasses are 
shown. Test samples were considered positive if their OD values were higher than the mean plus two standard deviations of 
10 pooled plasmas from malaria naïve donors from North America. The percentage prevalence was then calculated as 
described in figure 2.
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Levels of IgG subclasses antibody responses to MSP-1 subunits, MSP-636 and MSP-722 antigens Figure 5
Levels of IgG subclasses antibody responses to MSP-1 subunits, MSP-636 and MSP-722 antigens. The IgG1 (A) and 
IgG3 (B) antibody responses to the two allelic forms of each of the MSP-1 subunits, MSP-636 and MSP-722 were measured. The 
box plots depict median values with 25th- and 75th-percentile values represented by the bottom and top edges of boxes. Small 
diamonds indicate values that fall outside of the error bars. Statistically significant differences are depicted with the * (p < 0.05).
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cross-reactive antibodies. In fact, a previous study demon-
strated a high degree of cross-inhibition between antibod-
ies generated against the D and the F allelic forms of MSP-
1 [39].
IgG subclass analysis showed that IgG1 and IgG3 were the
predominant subclasses for most of the antigens studied,
consistent with previous studies [34,51,61]. While mixed
IgG1/IgG3 responses to all MSP antigens used was
detected, the relative proportions of these two subclasses
were different for the different MSP antigens, implying
that IgG class switching may be greatly influenced by the
characteristics of the antigen as previously suggested
[40,51,62]. It has been suggested that conserved antigens,
such as MSP-119, typically induce IgG1, while highly pol-
ymorphic antigens induce IgG3 [63]. Interestingly in this
study, such a correlation was not observed except for the
MSP-119 antigen which elicited more IgG1 than IgG3 as
previously observed [40,51,61,64]. In contrast, a mixed
response to the conserved MSP-636 was observed while a
previous study in southern-central Vietnam demonstrated
a skewing towards IgG1 [63]. Similarly, predominant
IgG3 responses were observed for the highly polymorphic
block 2 region (found within the p83 subunit) of MSP-1
in an African population [40] and for polymorphic MSP-
722 in Vietnam [63]. However, in the current study, MSP-
722 induced more IgG1 antibodies than IgG3 and MSP-
1d83 showed a mixed response, while MSP-1f83 elicited
Correlation of antibody responses between the two dimorphic alleles, MSP-1D and MSP-1F Figure 6
Correlation of antibody responses between the two dimorphic alleles, MSP-1D and MSP-1F. To determine if 
there was a correlation in antibody responses between the two allelic forms of MSP-1, a scatter plot of anti-MSP-1D versus 
MSP-1F total IgG antibody responses was generated. The lines represent the fitted values and the 95% confident interval lines. 
The Spearman correlation coefficients are shown in the upper left corner.
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more IgG1 antibodies than IgG3. These differences may
be due to differences in innate characteristics of the host
population or epidemiologic differences.
Conclusion
Observations from the current study provide insight into
the intricate pattern of acquired humoral responses to the
MSP-1/MSP-6/MSP-7 complex. The results demonstrate
that MSP-1/MSP-6/MSP-7 complex antigens are immuno-
genic in humans naturally exposed to P. falciparum infec-
tion in India, supporting the view that full size MSP-1 is a
particularly interesting vaccine candidate. In addition,
this study suggests that there may be a dysregulation in the
generation of optimal antibody responses to some of the
MSP-1 protein fragments in CM patients and it remains to
be determined if such differences contribute to suscepti-
bility of individuals to CM.
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